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Synthesis of 1,3-Selenazol-2(3H)-imines
Abstract
The reaction of N,N'-diarylselenoureas 16 with phenacyl bromide in EtOH under reflux, followed by
treatment with NH3 , gave N,3-diaryl-4-phenyl-1,3-selenazol-2(3H)-imines 13 in high yields (Scheme
2). A reaction mechanism via formation of the corresponding Se-(benzoylmethyl)isoselenoureas 18 and
subsequent cyclocondensation is proposed (Scheme 3). The N,N'-diarylselenoureas 16 were
conveniently prepared by the reaction of aryl isoselenocyanates 15 with 4-substituted anilines. The
structures of 13a and 13c were established by X-ray crystallography.
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2The  reaction  of  N,N’-diarylselenoureas  16 with  phenacylbromide  in  EtOH  under 
reflux, followed by treatment with NH3, gave N,3-diaryl-4-phenyl-1,3-selenazol-2(3H)-imines 
13 in high yields (Scheme 2). A reaction mechanism via formation of the corresponding Se-
(benzoylmethyl)isoselenoureas 18 and subsequent cyclocondensation is proposed (Scheme 3). 
The  N,N’-diarylselenoureas  16 were  conveniently  prepared  by  the  reaction  of  aryl 
isoselenocyanates  15 with  4-substituted  anilines.  The  structures  of  13a and  13c were 
established by X-ray crystallography.
3Introduction. – Since the discovery of the importance of Se as a microelement in 
bacteria and animals [1] and the function of the selenoenzyme glutathione peroxidase (PGx) as 
an antioxidant [2], the interest in organoselenium compounds has increased significantly. As a 
result,  a  large  series  of  organoselenium  compounds  was  prepared  as  GPx mimics,  e.g., 
diorgano di- and triselenides 1 and 2 [3–5] and selenaheterocycles 3–6 [6][7]. In recent years, 
isoselenocyanates  have  been  shown to be useful  building  blocks  for  the  synthesis  of  Se-
containing heterocycles [8]. 
Formulae
As a continuation of our studies toward the use of isoselenocyanates in the synthesis 
of  1,3-selenazole  derivatives  [9–14]  and  with  the  aim  of  preparing  1,3-selenazol-2(3H)-
imines,  we investigated the reaction of selenourea derivatives,  which are easily accessible 
from isoselenocyanates,  with  phenacyl  bromide.  Whereas  the  analogous  synthesis  of  1,3-
thiazol-2(3H)-imines  9 via the reaction  of  thioureas  7 with  phenacyl  bromides  8,  i.e. the 
Hantzsch condensation reaction [15], is well known [16–21] (Scheme 1), no synthesis of the 
corresponding 1,3-selenazol-2(3H)-imines has been reported so far.
Scheme 1
Very recently,  the group of  Koketsu and other groups reported on the synthesis  of 
some 1,3-selenazolidine-2-imines [22–25]. For example, N,N’-diisopropylselenourea (10) and 
2-bromo-2-methylpropanoyl bromide (11) in pyridine led to the 2-imino-1,3-selenazolidin-4-
one 12, the structure of which has been determined by X-ray crystallography [22] (Scheme 1). 
4In  the  present  paper,  we  describe  the  synthesis  of  some  N,3-diaryl-4-phenyl-1,3-
selenazol-2(3H)-imines 13 in a two step reaction from anilines 14, aryl isoselenocyanates 15, 
and phenacylbromide.
Results and Discussion. – The selenoureas 16 were prepared conveniently according 
to  the  previously  published  protocol  [26].  The  reaction  of  4-bromophenyl-  and  4-
chlorophenylisoselenocyanate (15a and 15b, resp.) with 4-substituted anilines 14 in tolouene 
in  the  presence  of  a  catalytic  amount  of  Et3N gave  16a–16f in  high  yield  as  crystalline 
materials (Scheme 2). Then, the solution of equimolar amounts of 16 and phenacylbromide in 
EtOH was heated to reflux for 2 h. The cooled mixture was poured into H2O and treated with 
aqueous  NH3 to  convert  the  formed  hydrobromides  17 into  the  free  1,3-selenazol-2(3H)-
imines 13 (Scheme 2). The products were isolated in good yield as colorless solids.
Scheme 2
The structure of the products was determined on the basis of their spectroscopic and 
analytical data and, in the cases of  13a and  13c, was established by X-ray crystallography 
(Figure). In both cases, the five-membered heterocycle is planar, but none of the aryl rings is 
coplanar with it. In 13c, the 4-(dimethylamino)phenyl residue is attached to the N-atom of the 
1,3-thiazole ring and the 4-bromophenyl ring is the substituent at the imine N-atom.
Figure. ORTEP Plot [27] of the molecular structure of 13a and 13c (50% probability 
ellipsoids, arbitrary numbering of the atoms)
5According to the NMR spectra, only one product was formed in the reactions with 
16a–16c and 16e, i.e., the formation of 13b,c and 13e occurred regioselectively. On the other 
hand, the products of the reaction with  16d and  16f  consisted of a  ca. 4:1 mixture of two 
isomeric  compounds.  For  example,  the  1H-NMR  spectrum  of  the  product  from  16d and 
phenacylbromide showed singlets at 6.37 and 6.41 ppm for H-C(5) and 2.27 and 2.32 ppm for 
Me, each with an intensity ratio of  ca. 4:1. We assign the structures  13d and  13d’ to these 
products.
Formulae 13d, 13d’
Based on the presented results and in analogy to the Hantzsch thiazole synthesis, we 
propose the following reaction  mechanism (Scheme 3):  nucleophilic  substitution  of  Br  in 
phenacylbromide by the Se-atom of selenourea  16 leads to the isoselenourea derivative  18, 
which subsequently undergoes a cyclocondensation to give the hydrobromide of 13 (cf. [17]). 
The plausible intermediate is  19, formed  via nucleophilic addition of an N-atom of  18 onto 
the C=O group.
Scheme 3
In the case of 18c, the cyclization occurs selectively via the more nucleophilic N-atom, 
bearing the 4-(dimethylamino)phenyl residue. The same selectivity was observed in the cases 
of the reactions with 16b and 16e with a 4-methoxyphenyl substituent. The formation of two 
isomers of type 13d and 13d’ in the reaction with 16d and 16f, respectively, which bear a 4-
methylphenyl  substituent  in  addition  to  a  4-bromo-  or  4-chlorophenyl  residue,  can  be 
explained with the smaller difference of the nucleophilicity of the two N-atoms due to the 
6lower electron-donating properties of the Me group in comparison with the Me2N and MeO 
groups.
In conclusion, a convenient synthesis of the little known 1,3-selenazol-2(3H)-imines 
from  diarylselenoureas  and  phenacylbromid  was  developed.  This  concept  can  easily  be 
applied for the preparation of differently substituted analogues.
We  thank  the  analytical  units  of  our  institute  for  spectra  and  analyses.  Financial 
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Experimental Part
1. General. See [28]. M.p.: Mettler-FP-5 or Büchi B-450 apparatus; uncorrected.  IR 
Spectra:  Perkin-Elmer-781 or  Perkin-Elmer-1600-FT-IR spectrophotometer.  1H-  and  13C-
NMR Spectra: Bruker-AC-300 or Bruker-ARX-300 instrument (300 and 75.5 MHz, resp.), in 
(D6)DMSO or CDCl3; multiplicity of C-atoms from DEPT spectra. MS: Finnigan MAT-90 or 
Finnigan SSQ-700 instrument (CI (NH3) or ESI). Elemental analyses were performed by the 
Mikroanalytisches Laboratorium des Organisch-chemischen Instituts der Universität Zürich. 
2.  Starting  materials.  4-(Bromophenyl)isoselenocyanate  (2a)  and  4-(chlorophenyl)-
isoselenocyanate (2b) were prepared according to the protocol described in [29], and  N,N'-
diarylselenoureas 3 were prepared according to [26]. All other chemicals were commercially 
available.
73. Synthesis of selenoureas  16. 3.1.  N,N’-Bis(4-bromophenyl)selenourea (16a) [30]. 
From 1.05 g (4 mmol) of 4-(bromophenyl)isoselenocyanate (15a) and 0.69 g (4 mmol) of 4-
bromoaniline  (14a):  1.6  g  (92%) of  16a.  M.p.  222.6–224.0° (toluene).  Creamy solid.  IR: 
3175s,  3021s,  2998s,  2832m,  1580m,  1552s,  1524s,  1485s,  1401m,  1333s,  1310s,  1271m, 
1254m,  1236m,  1217m,  1171w,  1094w,  1072s,  1016s,  920m,  851m,  827s.  1H-NMR 
((D6)DMSO):  10.25  (s,  2  NH);  7.52,  7.38  (AA’BB’,  JAB =  8.8,  8  arom.  H).  13C-NMR 
((D6)DMSO): 179.1 (s, CSe); 138.9, 117.5 (2s, 4 arom. C); 131.3, 126.7 (2d, 8 arom. CH). CI-
MS: 437 (18), 435 (38, [M+1]+), 433 (30), 431 (12), 357 (41), 356 (17), 355 (100), 354 (17), 
352 (80). Anal. calc. for C13H10Br2N2Se (433.00): C 36.06, H 2.33, N 6.47; found: C 35.52, H 
2.31, N 6.39. 
3.2. N-(4-Bromophenyl)-N’-(4-methoxyphenyl)selenourea (16b). From 0.5 g (1.9 mmol) 
of 15a and 0.23 g (1.9 mmol) of 4-methoxyaniline (14b): 0.57 g (80.3%) of 16b. M.p. 188.8–
190.3°  (CH2Cl2/hexane).  IR:  3175s,  3000s,  2836m,  1608m,  1587w,  1553s,  1527m,  1505s, 
1482m, 1463m, 1339s, 1297s, 1247s, 1218m, 1180m, 1166m, 1103m, 1068m, 1031m, 1015m, 
921w, 851w, 833s. 1H-NMR ((D6)DMSO): 10.08, 9.94 (2s, 2 NH); 7.50, 7.37 (AA'BB', JAB = 
8.8,  4  arom.  H);  7.26,  6.9l  (AA'BB',  JAB =  8.9,  4  arom.  H);  3.75  (s,  MeO).  13C-NMR 
((D6)DMSO): 178.8 (s, CSe); 157.0, 139.2, 132.1, 117.2 (4s, 4 arom. C); 131.1, 126.8, 126.6, 
113.7 (4d, 8 arom. CH); 55.1 (q, MeO). CI-MS: 387 (3), 385 (4, [M+1]), 383 (2), 307 (41), 
306 (17), 305 (100), 304 (13), 303 (60). Anal. calc. for C14H13BrN2OSe (384.13): C 43.77, H 
3.41, N 7.29; found: C 43.83, H 3.50, N 7.34.
3.3.  N-(4-Bromophenyl)-N’-[4-(dimethylamino)phenyl]selenourea (16c).  From  1.0  g 
(3.83 mmol) of 15a and 0.52 g (3.82 mmol) of 4-(dimethylamino)aniline (14c): 1.3 g (86%) 
of 16c. M.p. 171.3–174.0° (CH2Cl2/hexane). IR: 3172s, 3004s, 2884m, 2842m, 2800m, l611m, 
1575w, 1551s, 1531s, 1515s, 1483m,  1444w, 1397w, 1329s, 1309s, 1247m, 1224m, 1184w, 
1165w,  1128w,  1097w,  1064m,  1012m,  945m,  920m,  819s.  1H-NMR ((D6)DMSO): 10.01, 
89.74 (2s, 2 NH); 7.48, 7.37 (AA'BB',  JAB = 8.9, 4 arom. H); 7.13, 6.69 (AA'BB',  JAB = 8.9, 4 
arom. H); 2.89 (s, 2 Me). 13C-NMR ((D6)DMSO): 178.2 (s, CSe); 148.6, 139.4, 127.9, 117.1 
(4s, 4 arom. C); 131.0, 126.9, 126.1, 112.2 (4d, 8 arom. CH); 40.1 (q, 2 Me). ESI-MS: 400 
(100), 398 (86, [M+1]+), 396 (48). Anal. calc. for C15H16BrN3Se (397.17): C 45.36, H 4.06, N 
10.58; found: C 45.49, H 4.12, N 10.60.
3.4.  N-(4-Bromophenyl)-N’-(4-methylphenyl)selenourea (16d). From 0.5 g (1.9 mmol) 
of  15a and 0.2 g (1.9 mmol) of 4-methylaniline (14d): 0.6 g (88.2%) of  16d. M.p. 195.2–
197.0  (CH2Cl2/hexane).  IR:  3167s,  3001s,  2919w,  2832w,  1581m,  1551s,  1530m,  1506m, 
1484s, 1398w, 1380w, 1335s, 1238m, 1219m, 1175w, 1106w, 1098w, 1068m, 1014s, 921w, 
844w, 822s. 1H-NMR ((D6)DMSO): 10.25, 10.10 (2 s, 2 NH); 7.58, 7.45 (AA'BB', JAB = 8.8, 4 
arom. H); 7.33, 7.22  (AA'BB',  JAB = 8.3, 4 arom. H); 2.36 (s, Me).  13C-NMR ((D6)DMSO): 
178.6 (s, CSe); 139.2, 136.7, 134.6, 117.2 (4s, 4 arom. C); 131.1, 129.0, 126.7, 124.6 (4d, 8 
arom. CH); 20.4 (q, Me). CI-MS: 371 (4), 369 (6, [M+1]+), 367 (3), 291 (37), 290 (16), 289 
(100), 288 (14), 287 (66). Anal. calc. for C14H13BrN2Se (368.13): C 45.68, H, 3.56, N 7.61; 
found: C 45.60, H 3.64, N 7.60.
3.5. N-(4-Chlorophenyl)-N’-(4-methoxyphenyl)selenourea (16e). From 0.7 g (3.2 mmol) 
of 4-chlorophenylisoselenocyanat (15b) and  0.4 g (3.2 mmol) of 14b: 1.0 g (90.9%) of 16e. 
M.p.  187.9–189.1°C  (CH2Cl2/hexane).  IR:  3177s,  3001s,  2836m,  1609m,  1587w,  1554s, 
1525m, 1505s, 1486m, 1463m, 1441w, 1401w, 1336s, 1297s, 1248s, 1218m, 1180m, 1166m, 
1102m, 1090m, 1031m, 1018m, 922w, 852w, 834s, 821m. 1H-NMR ((D6)DMSO): 10.07, 9.94 
(2s, 2 NH); 7.42, 7.38 (AA’BB’, JAB = 8.9, 4 arom. H); 7.26, 6.91 (AA'BB', JAB = 8.9, 4 arom. 
H); 3.75 (s, Me).  13C-NMR ((D6)DMSO): 178.8 (s, CSe); 157.0, 138.7, 132.1, 129.0 (4s, 4 
arom. C); 128.1, 126.6, 126.5, 113.7 (4d, 8 arom. CH); 55.1 (q, Me). CI-MS: 343 (1), 341 (3, 
[M+1]+),  339  (1),  263  (14),  262  (11),  261  (73),  260  (18),  259  (100).  Anal.  calc.  for 
C14H13ClN2OSe (339.68): C 49.50, H 3.86, N 8.25; found: C 49.68, H 3.97, N 8.32.
93.6.  N-(4-Chlorophenyl)-N’-(4-methylphenyl)selenourea (16f). From 0.7 g (3.2 mmol) 
of  15b and  0.34  g  (3.2  mmol)  of  14d:  0.9  g  (88.2%)  of  16f.  M.p.  195.2–195.9 
(CH2Cl2/hexane). IR: 3172s, 3002s, 2921m, 2832w, 1584m, 1553s, 1506m, 1489m, 1403w, 
1380w,  1332s,  1238m,  1220w,  1175w,  1090s,  1017m,  921w,  849w,  824s.  1H-NMR 
((D6)DMSO): 10.42, 10.29 (2s, 2 NH); 7.69, 7.62 (AA'BB', JAB = 8.9, 4 arom. H); 7.52, 7.41 
(AA'BB', JAB = 8.3, 4 arom. H); 2.54 (s, Me). 13C-NMR ((D6)DMSO): 178.70 (s, CSe); 138.7, 
136.7, 134.6 (3s, 4 arom. C); 129.0, 128.2, 126.4, 124.6 (4d, 8 arom. CH); 20.4 (q, Me). CI-
MS: 327 (3), 325 (5, [M+1]+), 323 (3), 247 (14), 246 (12), 245 (74), 244 (19), 243 (100). 
Anal. calc. for C14H13ClN2Se (323.68): C 51.95, H 4.05, N 8.65; found: C 51.99, H 4.09, N 
8.75.
4. Reaction of N,N’-Diarylselenoureas 16 with Phenacyl Bromide. General procedure. 
Approximately 2.5 ml of abs. EtOH were added to a mixture of equimolecular amounts (1–2 
mmol) of 16 and phenacyl bromide. The mixture was stirred for 2 h under reflux. Then, the 
soln. was cooled to r.t., poured into cold H2O, and treated with aq. NH3. The solid obtained 
was filtered and dried (MgSO4). The mother liquor was concentrated  in vacuo, MeOH was 
added, and the white solid formed was again filtered and dried.
4.1.  3,N-Bis(4-bromophenyl)-4-phenyl-1,3-selenazol-2(3H)-imine (13a).  From  0.73  g 
(1.7 mmol) of 16a and 0.33 g (1.7 mmol) of phenacyl bromide: 0.7 g (77.8%) of 13a. M.p. 
193.1–194.4° (CHCl3/MeOH). White solid. IR: 3121w, 3103w, 3084w, 3055w, 1623s, 1574m, 
1556m,  1484m,  1475m,  1445w,  1396w,  1349m,  1298m,  1249m,  1144m,  1093w,  1062m, 
1013m, 1004m, 919m, 868m, 825m. 1H-NMR (CDCl3): 7.44–7.41 (m, 4 arom. H); 7.40–7.22 
(m, 3 arom. H); 7.21–7.06 (m, 4 arom. H); 6.94 (BB’ of AA’BB’, JAB = 8.6, 2 arom. H); 6.43 
(s, H–C(5)). 13C-NMR (CDCl3): 141.4, 137.5, 132.4, 128.4, 121.8, 117.2 (6s, 5 arom. C, C(2), 
C(4)); 132.8, 132.2, 130.5, 128.61, 128.58, 128.4, 123.2 (7d, 13 arom. CH); 98.0 (d, C(5)). 
CI-MS: 539 (7), 538 (12), 537 (52), 536 (27), 535 (100, [M+1]+), 534 (32), 533 (83), 532 (25), 
10
531 (35), 530 (10). Anal. calc. for C21H14Br2N2Se (533.12): C 47.31, H 2.65, N 5.25; found: C 
47.12, H 2.80, N 5.24. 
Suitable crystals of 13a for the X-ray crystal structure determination were obtained from 
Et2O by slow evaporation of the solvent at 5°.
4.2.  N-(4-Bromophenyl)-3-(4-methoxyphenyl)-4-phenyl-1,3-selenazol-2(3H)-imine 
(13b). From 0.3 g (0.78 mmol) of 16b, 0.15 g (0.78 mmol) of phenacyl bromide, 15–20 ml 
EtOH: 0.35 g (92%) of 13b. M.p. 214.9–215.3° (CH2Cl2/MeOH). IR: 3097w, 3055w, 3010w, 
2958w, 2928w, 2901w, 2830w, 1614s, 1602s, 1573s, 1557m, 1509s, 1490w, 1479s, 1462w, 
1449w, 1434w, 1347m, 1300m, 1285w, 1248s, 1146s, 1096w, 1067m, 1028m, 1006m, 919w, 
871m, 830m. 1H-NMR (CDCl3): 7.41, 6.96 (AA',BB’, JAB = 8.4, 4 arom. H); 7.25–7.08 (m, 7 
arom. H); 6.80 (BB' of AA'BB', JAB = 8.7, 2 arom. H); 6.41 (s, H–C(5)); 3.74 (s, MeO). 13C-
NMR (CDCl3): 158.8, 142.1, 131.1, 116.7 (4s, 5 arom. C, C(2), C(4)); 132.6, 129.8, 128.6, 
128.3, 128.0, 123.4, 114.3 (7d, 13 arom. CH); 97.5 (d, C(5)); 55.2 (q, MeO). CI-MS: 489 
(14), 488 (20), 487 (78), 486 (28), 485 (100, [M+l]+), 484 (26), 483 (46), 482 (15), 481 (14). 
Anal. calc. for C22H17BrN2OSe (484.25): C 54.57, H 3.54, N 5.78; found: C 54.15, H 3.59, N 
5.75.
4.3.  N-(4-Bromophenyl)-3-[(4-dimethylamino)phenyl]-4-phenyl-1,3-selenazol-2(3H)-
imine (13c). From 0.6 g (1.5 mmol) of 16c and 0.3 g (1.5 mmol) of phenacyl bromide: 0.55 g 
(73.3%)  of  13c.  M.p.  209.3–212.5°  (CH2Cl2/MeOH).  IR:  3106w,  2889w,  2861w,  2817w, 
1608s, 1571s, 1557m, 1528s, 1489m, 1475s, 1443m, 1374w, 1338s, 1316w, 1289m, 1248m, 
1232m,  1191w,  1138s,  1062s,  1000m,  918w,  860m,  825m,  809m.  1H-NMR (CDCl3): 7.40, 
6.89 (AA'BB',  JAB = 8.7, 4 arom. H); 7.26–7.04 (m, 7 arom. H); 6.63 (BB’ of AA’BB’,  JAB = 
8.8, 2 arom. H); 6.29 (s, H–C(5)); 2.90 (s, 2 Me).  13C-NMR (CDCl3): 143.1, 133.9, 123.1, 
116.2 (4s, 5 arom. C, C(2), C(5)); 133.3, 132.6, 129.5, 128.6, 128.5, 128.0, 123.2 (7d, 13 
arom. CH); 95.7 (d, C(5)); 40.7 (q, 2 Me). ESI-MS: 500 (46), 498 (100, [M+1]+), 496 (40), 
11
494 (24). Anal. calc. for C23H20BrN3Se (497.29): C 55.55, H 4.05, N 8.45; found: C 55.73, H 
4.08, N 8.38.
Suitable crystals of 13c for the X-ray crystal structure determination were obtained from 
Et2O by slow evaporation of the solvent at 5°.
5.4. N-(4-Bromophenyl)-3-(4-methylphenyl)-4-phenyl-1,3-selenazol-2(3H)-imine (13d). 
From 0.3 g (0.81 mmol) of 16d and 0.162 g (0.81 mmol) of phenacyl bromide: 0.3 g (78.9%) 
of  13d.  M.p.  193.4–193.8°  (CH2C12/MeOH).  IR:  3103w,  3051w,  3032w,  2918w,  1626s, 
1604s,  1574m,  1508m,  1488m,  1478m,  1441w,  1350m,  1292m,  1246m,  1141m,  1065m, 
1028w, 1006m, 916m, 868m, 826m. 1H-NMR (CDCl3, 2 isomers 4:1): 7.40, 6.92 (AA’BB’, JAB 
= 8.6, 4 arom. H); 7.30–7.05 (m, 9 arom. H); 6.41 (s, H–C(5), minor isomer); 6.37 (s, H–C(5), 
major isomer); 2.32 (s, Me, minor isomer); 2.27 (s, Me, major isomer).  13C-NMR (CDCl3): 
142.0, 137.7, 135.9, 132.9, 116.8 (5s,  5 arom. C, C(2), C(4)); 132.5, 132.0, 130.4, 130.2, 
129.6, 128.5, 128.4, 128.2, 128.1, 128.0, 123.2, 121.0 (12d, 13 arom. CH);  96.9 (d, C(5)); 
21.2 (s, Me, major isomer); 21.0 (s, Me, minor isomer). CI-MS: 473 (13), 472 (19), 471 (78), 
470  (28),  469  (100,  [M+1+]),  468  (26),  467  (46),  466  (16),  465  (14).  Anal.  calc.  for 
C22H17BrN2Se (468.25): C 56.43, H 3.66, N 5.98; found: C 56.33, H 3.64, N 6.00.
4.5.  N-(4-Chlorophenyl)-3-(4-methoxyphenyl)-4-phenyl-1,3-selenazol-2(3H)-imine 
(13e). From 0 .6 g (1.77 mmol) of  16e and 0.35 g (1.76 mmol) of phenacyl bromide: 0.6 g 
(77.92%) of  13e.  M.p.  200.0–200.7° (CH2Cl2/MeOH). IR:  3097w,  3052w,  3013w,  2956w, 
2930w, 2903w, 2833w, 1614s, 1603s, 1577s, 1556m, 1509s, 1481s, 1463m, 1451m, 1442m, 
1346m, 1309m, 1300m, 1285m, 1247s, 1168m, 1146s, 1087m, 1067m, 1029m, 1008m, 919w, 
872m, 832s, 821m.  1H-NMR (CDCl3): 7.26, 6.97 (AA'BB',  JAB = 8.7, 4 arom. H); 7.19–7.10 
(m, 7 arom. H); 6.79 (BB' of AA'BB',  JAB = 8.9, 2 arom. H); 6.35 (s, H–C(5)); 3.73 (s, Me). 
13C-NMR (CDCl3):  158.8,  151.8,  142.0,  133.0,  131.4,  129.0 (6s,  5  arom.  C,  C(2),  C(4)); 
130.2, 130.0, 129.7, 128.7, 128.2, 128.1, 122.8, 114.3 (8d, 13 arom. C); 96.5 (d, C(5)); 55.3 
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(q, MeO). CI-MS: 445 (6), 444 (11), 443 (44), 442 (26), 441 (100, [M+1]+), 440 (20), 439 
(49), 438 (18), 437 (17). Anal. calc. for C22H17ClN2OSe (439.80): C 60.08, H 3.90, N 6.37; 
found: C 60.01, H 3.95, N 6.38.
4.6. N-(4-Chlorophenyl)-3-(4-methylphenyl)-4-phenyl-1,3-selenazol-2(3H)-imine) (13f). 
From 0.5 g (1.5 mmol) of 16f and 0.3 g (1.5 mmol) of phenacyl bromide: 0.6 g (92.3%) of 
13f. M.p. 191.1–191.3° (CH2Cl2/MeOH). IR: 3108w, 3051w, 3033w, 2918w, 2855w, 1630s, 
1620s, 1606s, 1580s, 1509m, 1481s, 1441m, 1350m, 1307w, 1293m, 1246m, 1165w, 1141s, 
1105w,  1087m,  1066m,  1028w,  1009m,  916m,  869m,  831m,  821m.  1H-NMR  (CDCl3,  2 
isomers 4:1): 7.30–6.95 (m, 13 arom. H); 6.44 (s, H–C(5), minor isomer); 6.39 (s, H–C(5), 
major isomer); 2.32 (s, Me, minor isomer); 2.27 (s, Me, major isomer).  13C-NMR (CDCl3): 
142.1, 142.0, 137.5, 132.8 (4s,  5 arom. C, C(2), C(4)); 130.3, 130.2, 129.7, 129.3, 128.7, 
128.6,  128.3,  128.1,  123.0,  121.4  (10d,  13 arom.  H);  97.3  (d,  C(5));  21.2  (s,  Me,  major 
isomer); 21.0 (s, Me, minor isomer). CI-MS: 429 (6), 428 (11), 427 (44), 426 (26), 425 (100, 
[M+l]+),  424 (20), 423 (49), 422 (19), 421 (17). Anal.  calc. for C22H17ClN2Se (423.80): C 
62.35, H 4.04, N 6.61; found: C 62.19, H 4.13, N 6.60.
5. X-Ray Crystal-Structure Determination of 13a and 13c (Table and Figs. 1 and 2)2). 
All  measurements  were  performed  on  a  Nonius  KappaCCD diffractometer  [31] using 
graphite-monochromated  MoKα radiation  (λ 0.71073  Å)  and  an  Oxford  Cryosystems 
Cryostream 700 cooler. The data collection and refinement parameters are given in the Table, 
and views of the molecules are shown in the Figure. Data reduction was performed with HKL 
Denzo and Scalepack [32]. The intensities were corrected for Lorentz and polarization effects, 
and absorption corrections based on the multi-scan method [33] were applied. The structure of 
2 ) CCDC-757788–757789 contain the supplementary crystallographic data for this paper. 
These data can be obtained free of charge from the  Cambridge Crystallographic Data  
Centre via http://www.ccdc.cam.ac.uk/data_request/cif.
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13a was solved by direct methods using SIR92 [34], which revealed the positions of all non-
H-atoms.  The structure of  13c was solved by heavy-atom  Patterson methods [35],  which 
revealed the positions of the Br- and Se-atoms.  All remaining non-H-atoms were located in a 
Fourier expansion of the  Patterson solution, which was performed by DIRDIF94 [36]. The 
non-H-atoms were refined anisotropically.  All of the H-atoms were placed in geometrically 
calculated positions and refined using a riding model where each H-atom was assigned a fixed 
isotropic displacement parameter with a value equal to 1.2Ueq of its parent atom (1.5Ueq for 
Me groups).  The refinement of each structure was carried out on F2 using full-matrix least-
squares procedures, which minimized the function Σw(Fo2 – Fc2)2. Corrections for secondary 
extinction were not applied. In the case of 13c, several large peaks of residual electron density 
remain unaccounted for and cannot be associated with any logical chemical species.  It is 
presumed that they are artefacts caused by the inferior data quality. Neutral atom scattering 
factors for non-H-atoms were taken from [37a], and the scattering factors for H-atoms were 
taken from [38]. Anomalous dispersion effects were included in Fc [39]; the values for f ' and 
f " were those of [37b]. The values of the mass attenuation coefficients are those of [37c]. All 
calculations were performed using the SHELXL97 [40] program.
Table. Crystallographic Data for Compounds 13a and 13c 
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Crystallized from Et2O Et2O
Empirical formula C21H14Br2N2Se C23H20BrN3Se
Formula weight 533.06 497.24
Crystal color, habit colorless, needle colorless, needle
Crystal dimensions [mm] 0.05 × 0.05 × 0.35 0.02 × 0.05 × 0.27
Temperature [K] 160(1) 160(1)
Crystal system monoclinic triclinic
Space group P21/c P
Z 4 2
Reflections for cell determination 45874 64681
2θ range for cell determination [°] 4–50 4–55
Unit cell parameters a [Å] 5.7698(2) 5.9821(2)
b [Å] 23.1139(8) 10.9232(5)
c [Å] 14.3302(5) 15.9088(7)
α [°] 90 100.029(2)
β [°] 93.394(2) 97.181(3)
γ [°] 90 99.019(3)
V [Å3] 1907.8(1) 998.53(7)
Dx [g cm–1] 1.856 1.654
µ(MoKα) [mm–1] 6.176 3.900
Scan type φ and ω φ and ω
2θ(max) [°] 50 55
Transmission factors (min; max) 0.522; 0.744 0.770; 0.928
Total reflections measured 31960 22568
Symmetry independent reflections 3356 4556
Reflections with I > 2σ(I) 2501 3474
Reflections used in refinement 3356 4556
Parameters refined 235 255
Final R(F)  [I > 2σ(I) reflections] 0.0360 0.0812
19
wR(F2)  (all data) 0.0769 0.2430
Weighting parameters [a; b]a) 0.0342; 1.1353 0.1645; 1.3205
Goodness of fit 1.042 1.089
Final ∆max/σ 0.001 0.001
∆ρ (max; min) [e Å–3] 0.44; –0.47 3.62; –0.75














































































14a R1 = Br
     b R1 = MeO
     c R1 = (Me2)N
     d  R1 = Me
15a R2 = Br
    b R2 = Cl
16a R1 = R2 = Br
     b R1 = MeO, R2 = Br
     c R1 = (Me2)N, R2 = Br
16d R1 = Me, R2 = Br
     e R1 = MeO, R2 = Cl

















13a R1 = R2 = Br
     b R1 = MeO, R2 = Br
     c R1 = (Me2)N, R2 = Br
13d R1 = Me, R2 = Br
     e R1 = MeO, R2 = Cl

































































Se Ph C CH2Br
O
EtOH, reflux N
Se N
Ph Ar1
Ar2
NH3/H2O
r.t.
1.
2.
